Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161346 | 0.74 | TGFBR1 (0.34) | TGFBR1RAB9A | |
| SCHEMBL1673128 | 0.73 | — | — | |
| SCHEMBL19806300 | 0.71 | PIM1 (0.34) | PIM1SMN1; SMN2 | |
| SCHEMBL15326962 | 0.71 | CCR1 (0.64) | TGFBR1MAPK14 | |
| SCHEMBL29590093 | 0.71 | CCR1 (0.64) | TGFBR1MAPK14 | |
| SCHEMBL8202122 | 0.70 | DAPK3 (0.47) | TGFBR1PIM1NPC1CASP3RAB9A | |
| SCHEMBL2458453 | 0.70 | CCR1 (0.41) | RAB9ASMN1; SMN2 | |
| SCHEMBL20447113 | 0.69 | AAK1 (0.45) | TGFBR1MAPK14NPC1RAB9A | |
| SCHEMBL20090330 | 0.69 | IDH1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL31178133 | 0.69 | DAPK3 (0.46) | TGFBR1PIM1NPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018017633-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885TGFBR2 2/4885MAPK14 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.